Advanced Crohn’s Therapies Show Similar Safety - Poll - MDSpire

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

By
Doug Brunk
February 19, 2026
2 min

MDSpire News

Share

Original Source(s)

Mdspire News

Advanced Crohn’s Therapies Show Similar Safety

by Doug Brunk
February 19, 2026

Related Content

Bmc Gastroenterology

Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease

by Ragaey Ahmad Eid, Nada Atteya Fakhry, Doaa Mabrouk Ahmed, Mahmoud Hodeib
July 17, 2026

Jama Network Open

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management

by Qi Jian, Naueen A. Chaudhry, Fanxing Du, Ellen Zimmermann, Tianze Jiao
April 29, 2026

Journal Of Gastroenterology

Advanced Crohn’s Therapies Show Similar Safety

Original Source(s)

Advanced Crohn’s Therapies Show Similar Safety

Related Content

Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management

Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies